Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchRavulizumabRavulizumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Summary of COVID-19 ravulizumab studies

Studies   Meta Analysis   Hide extended summaries

201 patient ravulizumab ICU RCT: 8% higher mortality (p=0.76).
RCT 201 mechanically ventilated patients with severe COVID-19 showing no significant difference in mortality with ravulizumab. The study was terminated early due to futility.

Mar 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023000826, https://c19p.org/annane

280 patient ravulizumab late treatment RCT: 1% lower mortality (p=0.98), 53% higher progression (p=0.13), 24% higher need for oxygen therapy (p=0.57), and 3% lower hospital discharge (p=0.86).
RCT 417 hospitalized COVID-19 patients in the UK showing no significant difference in a composite primary endpoint (time to death, invasive mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular organ support, or renal failure) with baricitinib or ravulizumab. The trial was stopped early due to futility. There were no significant differences in secondary outcomes including disease severity, days to discharge, mortality, or adverse events.

Dec 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023003764, https://c19p.org/hall3
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit